Insiders Buying Outlook Therapeutics And 2 Other Stocks
Insiders Buying Outlook Therapeutics And 2 Other Stocks
Although U.S. stocks closed mixed on Thursday, there were a few notable insider trades.
儘管週四美國股市收盤漲跌互現，但仍有一些值得注意的內幕交易。
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
當內部人士購買股票時，這表明他們對公司前景充滿信心，或者他們認爲股票很划算。無論哪種方式，這都預示着做多該股的機會。不應將內幕購買視爲做出投資或交易決策的唯一指標。充其量，它可以爲購買決定提供信心。
Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.
以下是最近一些值得注意的內幕收購。欲了解更多，請查看 本辛加的內幕交易 平台。
CION Investment
CION 投資
- The Trade: CION Investment Corporation (NYSE:CION) Co-Chairman & Co-CEO Mark Gatto acquired a total of 1,150 shares an average price of $11.02. To acquire these shares, it cost around $12,673.
- What's Happening: On March 14, CION Invt posted downbeat quarterly earnings
- What CION Investment Does: CION Investment is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company.
- 貿易：CION投資公司（紐約證券交易所代碼：CION）聯席董事長兼聯席首席執行官馬克·加託 共收購了 1,150 股股票 平均價格爲11.02美元。收購這些股票的成本約爲12,673美元。
- 發生了什麼：3月14日，CION Invt公佈了悲觀的季度收益
- CION Investment做什麼：CION Investment是一家外部管理、非多元化的封閉式管理投資公司，已選擇作爲業務發展公司接受監管。
Outlook Therapeutics
Outlook 療法
- The Trade: Outlook Therapeutics, Inc. (NASDAQ:OTLK) Director Yezan Munther Haddadin acquired a total of 1,881 shares at an average price of $11.82. To acquire these shares, it cost around $22,242.
- What's Happening: On March 27, BTIG upgraded the stock from Neutral to Buy and announced a $50 price target.
- What Outlook Therapeutics Does: Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
- 交易：Outlook Therapeutics, Inc.（納斯達克股票代碼：OTLK）董事耶贊·芒特·哈達丁共收購了1,881股股票，平均價格爲11.82美元。收購這些股票的成本約爲22,242美元。
- 發生了什麼：3月27日，BTIG將該股從中性上調至買入，並宣佈了50美元的目標股價。
- Outlook Therapeutics做什麼：Outlook Therapeutics Inc是一家臨床階段的生物製藥公司，專注於開發和商業化適用於各種眼科適應症的單克隆抗體或單克隆抗體 ONS-5010。
Don't forget to check out our premarket coverage here
別忘了在這裏查看我們的上市前報道
Rocket Companies
火箭公司
- The Trade: Rocket Companies, Inc. (NYSE:RKT) Director Matthew Rizik bought a total of 301 shares at an average price of $14.57. To acquire these shares, it cost around $4,386.
- What's Happening: On March 18, B of A Securities analyst Mihir Bhatia maintained Rocket Companies with an Underperform and raised the price target from $7 to $8.
- What Rocket Companies Does: Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit.
- 貿易：火箭公司（紐約證券交易所代碼：RKT）董事馬修·裏齊克 共購買了 301 股股票 平均價格爲14.57美元。收購這些股票的成本約爲4,386美元。
- 發生了什麼：3月18日，B of A Securities分析師米希爾·巴蒂亞維持了火箭公司的表現不佳，並將目標股價從7美元上調至8美元。
- 火箭公司做什麼：火箭公司是一家金融服務公司，最初成立於1985年，名爲Rock Financial，目前總部設在底特律。
譯文內容由第三人軟體翻譯。